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Here, we present the first study of a human neuromuscular disorder at transcriptional and pro-
teomic level. Autosomal dominant facio-scapulo-humeral muscular dystrophy (FSHD) is caused
by a deletion of an integral number of 3.3-kb KpnI repeats inside the telomeric region D4Z4 at
the 4q35 locus. We combined a muscle-specific cDNA microarray platform with a proteomic
investigation to analyse muscle biopsies of patients carrying a variable number of KpnI repeats.
Unsupervised cluster analysis divides patients into three classes, according to their KpnI repeat
number. Expression data reveal a transition from fast-glycolytic to slow-oxidative phenotype in
FSHD muscle, which is accompanied by a deficit of proteins involved in response to oxidative
stress. Besides, FSHD individuals show a disruption in the MyoD-dependent gene network
suggesting a coregulation at transcriptional level during myogenesis. We also discuss the hy-
pothesis that D4Z4 contraction may affect in trans the expression of a set of genes involved in
myogenesis, as well as in the regeneration pathway of satellite cells in adult tissue. Muscular
wasting could result from the inability of satellite cells to successfully differentiate into mature
fibres and from the accumulation of structural damages caused by a reactive oxygen species
(ROS) imbalance induced by an increased oxidative metabolism in fibres.
Received: January 25, 2006
Revised: June 12, 2006
Accepted: June 12, 2006
Keywords:
2-D electrophoresis / FSHD / Gene expression profile / Human muscle / Mass
spectrometry
Proteomics 2006, 6, 5303–5321 5303
1 Introduction
Facio-scapulo-humeral muscular dystrophy (FSHD,
FSHMD1A, OMIM #158900) is an autosomal dominant
myopathy of variable penetrance, with a wide and hetero-
geneous spectrum of clinical features. In classical FSHD,
there is an early involvement of facial and scapular muscles.
The major locus of this disorder, FSHD1, maps to the sub-
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telomeric region of chromosome 4q (4q35), specifically the
D4Z4 low copy GC-rich repeat consisting of a perfect array of
3.3 kb KpnI units (U). This polymorphic array varies be-
tween 11 and 150 U in the general population, whereas
patients, because of deletion of an integral number of
repeats, show a reduction from 1 to 10 U [1, 2]. There is an
inverse relationship among the residual repeat size, the
severity and the age at onset of disease. Four to seven repeats
are found in the most common forms of FSHD, eight to ten
are associated with a milder phenotype and reduced pene-
trance, whereas one to three repeats are characteristic of
early onset severe disease [3–5]. No specific transcripts
derived from this locus have yet been identified and it is
unclear how a deletion in a noncoding genomic region caus-
es a muscle-specific phenotype. Gabellini et al. [6] proposed
that FSHD might be caused by reduced affinity between
negative transcriptional complexes and the D4Z4 region,
leading to inappropriate activation of genes (FRG1, FRG2
and ANT1) proximal to the 4q35 region. After generating
transgenic mice overexpressing in skeletal muscle FRG1,
FRG2 or ANT1, they identified FRG1 as the gene respon-
sible for FSHD pathogenesis, as only FRG1 transgenic
mice develop a muscular dystrophy with features char-
acteristic of the human disease, while FRG2 and ANT1
transgenic mice seem normal [7].
However, other molecular mechanisms have also been
proposed [8–11]. Recent evidence suggests that contraction
of the D4Z4 repeat alone is not sufficient to cause the dis-
ease and that a polymorphic segment of 10 kb directly dis-
tal to D4Z4, which exists in the population with nearly
equal frequencies, is also important. FSHD is uniquely
associated with the 4qA allele variant containing the b-
satellite, a sequence previously associated with hetero-
chromatin [12]. Therefore, manifestation of the FSHD
phenotype requires both contraction of the D4Z4 repeat
within 1–10 U, and its occurrence on a 4qA telomeric
allele. This observation and the fact that many D4Z4 CpG
methylation sensitive restriction sites are significantly
hypomethylated in FSHD patients compared to normal
individuals, suggest that FSHD can be considered as a
chromatin disease. Winokur et al. [13] proposed that FSHD
arises from a defect in myogenic differentiation which may
be related to global effects on gene expression mediated by
nuclear positioning and alterations in nuclear envelope as-
sociation, rather than by a position effect on 4q35-specific
gene expression. They observed that, in contrast to most
other telomers, the FSHD region at 4q35.2 localizes to the
nuclear periphery and the nuclear lamin A/C protein is
required for FSHD chromatin localization to the nuclear
envelope [14]. Disruption of the peripheral chromatin
organization is seen in neuromuscular disorders such as
Emery-Dreifuss muscular dystrophy (EDMD) and in lamin
A deficient dystrophic mice [15, 16]. In these diseases,
mutations of nuclear envelope proteins such as lamin A/C
and emerin result in alterations of gene expression pat-
terns and differentiation.
We have started a genomic study of the global pattern
of gene expression in FSHD muscle. Since disease sever-
ity is related to the length of the p13E-11 fragment (i.e.
the number of remaining KpnI units), we analysed a
series of genetically characterized FSHD patients with a
range of D4Z4 allele sizes at the contracted 4qter region
and with canonical phenotypes of varying grades of clin-
ical severity, and we have compared microarray-based
gene expression profiles with the protein patterns from
the same patients.
Our aim was to exclude genes and proteins with limited
effects and identify biomarkers strongly associated with the
disease. This approach has enabled us to define molecular
differences between FSHD and normal deltoideous muscles
and to correlate a series of altered transcripts and proteins to
the genomic structure of the 4qter region in FSHD patients.
We have detected alteration in expression levels of transcripts
and proteins controlled by the muscle-specific transcription
factor MyoD, and have demonstrated that impairment in
differentiation from slow to fast muscle fibres correlates to
the size of the contracted D4Z4 region. In addition, we have
identified transcripts and proteins whose expression profiles
are altered according to the genotype.
2 Materials and methods
2.1 Patient selection
We analysed 11 FSHD patients carrying different numbers
of KpnI repeat units on the pathogenic 4q35 allele (nine
males and two females) whose age at biopsy ranged from to
69 years. The investigation was carried out in accordance
with the principles outlined in the 1989 declaration of Hel-
sinki after approval of the ethical committees of the colla-
borating institutions. Muscle biopsies from subjects in
whom a muscle disease was excluded by both clinical and
histopathological criteria were used as controls.
Diagnostic criteria for FSHD followed the guidelines
proposed by the European Expert Group on FMD [17]. Neu-
rological examination was performed in all patients by E.R.
at the Institute of Neurology of the Catholic University of
Rome or at the Center for Neuromuscular Diseases (UILDM
Sezione Laziale, Rome). For clinical classification we adopted
a scale of clinical severity taking into account the extent of
weakness in various muscular regions, and the spread of
symptoms to pelvic and leg muscles; higher scores were
assigned to patients with involvement of pelvic and proximal
lower limb muscles [5].
2.2 Tissue collection and storage
After obtaining written consent, ,30 mg muscle tissue was
obtained by surgical biopsies from the mid-portion of the left
deltoideus muscle. This muscle was chosen because it is
relatively unaffected by the dystrophic process in FSHD.
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Therefore, differences between healthy and affected individ-
uals would probably reflect the primary defect rather than
secondary consequences of muscle degeneration.
One portion of each biopsy was frozen in liquid nitrogen-
cooled isopentane for histochemistry and immunocy-
tochemistry analyses, and another was frozen and preserved
at 2807C for biochemical and molecular studies.
2.3 Histochemistry and immunocytochemistry
A panel of histochemical and histoenzymatic diagnostic
reactions was performed on 10 mm transverse cryostat sec-
tions as described previously [18]. Immunohistochemical
study of muscle biopsies was performed according to pre-
viously described protocols [19]. The primary antibodies used
were monoclonal anti-Myosin fast type heavy chain (Novo-
castra Laboratories, Newcastle upon Tyne, UK) diluted 1/20,
monoclonal anti-Myosin slow type heavy chain (Novocastra
Laboratories) diluted 1/50 and monoclonal anti-Myosin
developmental type heavy chain (Novocastra Laboratories)
diluted 1/25. Detection of immunocomplexes was performed
using the appropriate peroxidase-conjugated secondary anti-
body (Dakocytomation, Glostrup, Denmark). These tests
were performed to grade the patients’ samples for different
physiopathological traits as reported in Table 1.
To characterize fibre types distribution, at least
1000 fibres from eight microscopic fields were analysed in
each patient and control (Table 2, Fig. 1). The mean fibre di-
ameter of each fibre type was determined by computational
analysis of at least 200 fibres using the software MCID Basic
(Version 7.0, Imaging Research, St. Catharines, ON,
Canada).
2.4 Molecular characterization of patients
Genotyping was performed as described in [20]. Briefly,
lymphocytes were isolated from human peripheral blood
and embedded in agarose plugs before DNA extraction. The
size of the 4q35-EcoRI-fragments was determined by pulse
field gel electrophoresis (PFGE) and Southern hybridiza-
tion. To distinguish between the fragments of EcoRI (BlnI
resistant) and 10q26 (BlnI sensitive) the DNA was digested
with EcoRI/HindIII and EcoRI/BlnI. Southern blot was
hybridized with a p13E-11 probe labelled with P32 dATP.
Table 1. Clinical and molecular data of the FSHD patients analyzed in this study
Biopsy
number
Fragment
length
(Kb)
Age at
biopsy
(years)
Sex Clinical
severitya)
Fibrosis Inflam-
mation
Regen-
erating
fibres
Rag-
gedred
fibres
Myopatic
features
1 27 69 M 4 2 2 No Some 1
2 27 51 M 3.5 2 2 Rare Some 11
3 26 20 M 2.5 2 2 No Rare 11
4 23 27 M 2 2 2 No 2 11
5 23 53 F 1.5 2 2 Rare Some 1
6 21 30 M 2.5 2 2 No 2 1
7 19 15 M 1.5 2 1 No 2 11
8 16 32 M 3 2 2 No 2 11
9 10 13 M 4 2 1 No 2 1
10 10 8 F 4 2 1 rare 2 11
11 10 21 M 4 2 2 No 2 1
– absent
1 minimal
11mild
a) Clinical severity scale adopted in this study:
0.5 Facial weakness
1 Mild scapular involvement without limitation of arm abduction; no awareness of disease symptoms is possible
1.5 Moderate involvement of scapular and arm muscles or both (arm abduction .607 and strength 3 in arm muscles); no involvement of
pelvic and leg muscles
2 Severe scapular involvement (arm abduction ,607 on at least one side); strength ,3 in at least one muscular district of the arms; no
involvement of pelvic and leg muscles
2.5 Tibioperoneal weakness; no weakness of pelvic and proximal leg muscles
3 Mild weakness of pelvic and proximal leg muscles or both (strength 4 in all these muscles); able to stand up from a chair without
support
3.5 Moderate weakness of pelvic and proximal leg muscles or both (strength 3 in all these muscles); able to stand up from a chair with
monolateral support
4 Severe weakness of pelvic and proximal leg muscles or both (strength,3 in at least one of these muscles); able to stand up from a chair
with double support; able to walk unaided
4.5 Unable to stand up from a chair; walking limited to several steps with support; may use wheelchair for most activities
5 Wheelchair bound
Muscle strength was evaluated by using the Manual Muscle Testing Scale
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Figure 1. Representative muscle sections from
FSHD patient number 9 (shown in panel 1) and
from a normal control (panel 2), displaying
immunocytochemistry detection of myosin fast
type heavy chain and myosin slow type heavy
chain. In dark grey: II fibres; light grey: I fibres.
Patient number 9 (= 10 kb) exhibits an increased
percentage of I fibres compared to a normal del-
toideous muscle, used as control (Table 2).
Table 2. Average fibre diameter and fibre types composition in
FSHD deltoideous muscle tissue, determined for each
patient enrolled in this study
Biopsy
number
% Fibres
type I
% Fibres
type II
Average fibre
diameter (m)
type I/type II
1 51 49 686 7/696 6
2 45 55 776 10/756 8
3 56 44 596 11/636 9
4 40 60 756 12/726 8
5 53 47 606 8/576 8
6 45 55 586 6/576 6
7 57 43 656 7/696 8
8 42 58 566 11/556 8
9 67 33 446 8/476 7
10 72 28 296 6/326 5
11 62 38 526 7/566 6
2.5 Microarray experiments
DNA microarrays were prepared by spotting PCR-amplified
inserts from a collection of 4 801 3’-end-specific cDNA
clones, corresponding to transcripts expressed in human
skeletal muscle and heart, in duplicate on glass slides. This
microarray platform, named Human Muscle Array 2.0
(http://muscle.cribi.unipd.it/microarrays/human.html) has
been deposited in the GEO database under the accession
code GPL2011. We used a GenPackArray 21 spotting device
(Genetix, UK) with 16 stealth micro pins (TeleChem, CA,
USA). Microarray construction was carried out as described
in [21].
2.6 RNA purification and labelling
Frozen patient biopsies were homogenized for 3–5 min
using an ultraturrax-T8 blender (IKA-Werke, Staufen, Ger-
many) in five volumes of TRIZOL reagent (Invitrogen/Life
Technologies). Total RNA was purified using RNeasy Mini
Kit (Qiagen, Hilden, Germany). A 100 ng aliquot of total
RNA was used for quantification and quality control using
the RNA 6000 LabChip kit and Agilent Bioanalyzer 2100
(Agilent Technologies, Palo Alto, CA, USA). Linear amplifi-
cation of mRNA starting from 100 ng of total RNA was car-
ried out using the Message-Amp-aRNA kit (Ambion, TX,
USA) with two consecutive amplification steps according to
the manufacturer’s recommendations. Fluorescent cDNA
targets were prepared by direct labelling of 1.5 mg aRNA
from each sample, performing a retro-transcription reaction
in 30 mL of final volume with 1 mL of Cy3 or Cy5 deoxyr-
ibonucleotides (Amersham Pharmacia Biotech, Barcelona,
Spain).
2.7 Microarray hybridization
Labelled cDNA was concentrated by ethanol precipitation
and dissolved in 45 mL of hybridization buffer. Patient and
control labelled cDNAs were mixed before precipitation.
After denaturation at 907C for 2 min, targets were applied
directly on the microarray, covered with a 40 mm624 mm
cover slip and enclosed in a slide chamber (HybChamber,
GeneMachines, San Carlos, CA, USA), humidified with
100 mL of 26 SSC. Hybridization was performed overnight
at 427C by immersion in a water bath (W28, Grant, Cam-
bridge, UK). The following posthybridization washes were
performed using 16 SSC, 0.1% SDS for 4 min at 427C,
0.16 SSC, 0.1% SDS for 4 min at room temperature and
0.26 SSC for 2 min at room temperature. Each experiment
was performed at least twice using different microarray
slides in which the Cy3 or Cy5 labelling was reversed be-
tween sample and reference RNAs, resulting in four values
for each array probe. After spot normalization, as described
below, the average value of spot replicates for each patient
was calculated.
2.8 Statistical analysis of expression data
Array scanning was carried out on a GSI Lumonics LITE
dual confocal laser scanner with ScanArray Microarray
Analysis Software, and raw scanner images were analysed
with QuantArray Analysis Software (GSI Lumonics, Ottawa,
Canada). Normalization of the expression levels was per-
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formed with the program MIDAS (TIGR Microarray Data
Analysis System, http://www.tigr.org/software/tm4/) [22].
Global and Lowess mean normalizations across element
signal intensity were performed, and then logarithmic
transformation was applied at each expression ratio. Values
with SDs among single-patient-gene replicates greater than
0.5 were excluded from the final dataset. Detection of differ-
entially expressed genes was achieved using both the Statis-
tical Analysis of Microarrays program (SAM, http://www-
stat.stanford.edu/tibs/SAM/index.html) [23] and J-Express
software (J-Express, www.molmine.com/index_p.html) [24].
The detection of discriminating genes among different
groups of patients was performed with the program Predic-
tion Analysis of Microarrays (PAM, http://www-stat.-
stanford.edu/,tibs/PAM/) [25]. k-Means and profile simi-
larity search were performed with J-Express; cluster analysis
was performed with MIDAW [26] and TIGR MeV 3.0. [22].
2.9 Cluster analysis of expression profiles of single
patients
The dataset obtained from the microarray analysis of FSHD
muscle samples comprises a matrix of 4.992 rows (genes)
and 11 columns (one for each patient). A two-way hier-
archical cluster analysis, with Pearson coefficient measure
and complete linkage method for the calculation of the dis-
tance among clusters, was performed on the whole dataset.
Furthermore, k-means cluster analysis using Pearson and
Euclidean distance measures, and similarity profile search-
ing were performed to find out transcripts with an increasing
or decreasing profile according to disease progression.
2.10 Quantitative RT-PCR
We used quantitative RT-PCR to test the expression level of
selected genes potentially involved in the mechanism of
FSHD. A 1.5 mg aliquot of purified total RNA from each
sample was used to perform three independent cDNA syn-
thesis in a final volume of 10 mL, using oligo-dT primer and
Superscript reverse transcriptase (Life Technologies, Barce-
lona, Spain). A 1 mL aliquot of diluted first-strand cDNA was
amplified in 10 mL PCR reactions using SYBR Green I
chemistry, according to the recommendations of Applied
Biosystems. Gene-specific primers for amplification of frag-
ments close to the 3’-end of each transcript, ranging from
150 to 220 bp in length, were designed using Primer3
software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_
www.cgi). To avoid the amplification of contaminant geno-
mic DNA, primers from different exons, separated by long
(more than 1000 bp) introns were used. Dissociation curves
were used to assess the specificity of the amplicon. PCR
reaction was performed in a GeneAmp 9600 thermal cycler
coupled with a GeneAmp 5700 Sequence Detection System
(Applied Biosystems, Foster City, CA, USA). Cycling condi-
tions were 15 min denaturation at 957C, followed by
40 cycles of 30 s denaturation at 957C, 1 min annealing at
637C and a final 5 min elongation step at 727C. To evaluate
differences in gene expression we used a relative quantifica-
tion method based on the standard curve approach [27, 28].
Expression levels were compared to an endogenous control
transcript (polymerase RNA II DNA directed polypeptide J,
POLR2J) that is equally expressed under the experimental
conditions assayed in our work.
2.11 Bioinformatic analysis of gene promoters
Promoter regions of significantly altered transcripts obtained
from microarray data were analysed using Genomatix Suite
(version 2004, http://www.genomatix.de). Gene2Promoter
software package was used to identify common transcription
factor binding sites and GEMS Launcher software package
was used to automatically define potential promoter frames
using default parameters.
2.12 Proteome analysis
The samples were prepared as follows: ground frozen tissue
was solubilized in a lysis buffer consisting of 7 M urea,
2 M thiourea [29], 2% CHAPS, 10 mM 1,4-DTT and a pro-
tease inhibitor cocktail (Sigma-Aldrich) and sonicated for
30 s. Samples were homogenized, extracted and quantitated
separately by 2-D Quant kit (GE Healthcare). Protein recov-
ery was 12.5 6 0.31%.
2.13 MHC composition
SDS electrophoresis of the muscle extracts was performed as
described in [30] using a discontinuous buffer system with a
4% T stacking gel (pH 6.8) and a 6% T, constant concentra-
tion, 37% w/v glycerol (pH 8.8) running gel. Samples were
separated at 100 V, overnight. Gels were stained with SYPRO
Orange and scanned at 570 nm with Typhoon laser densi-
tometer (Amersham Biosciences). Protein band quantitation
was achieved using Image Quant (Molecular Dynamics)
software. Molecular weight markers (GE, Amersham) con-
taining MHC from rabbit (MW 212 kDa) and a2-macro-
globulin (170 kDa) were run in a separate lane as described
in [39].
2.14 2-DE
Sample preparation was performed as mentioned above. For
analytical gels, 2-DE was carried out in 18 cm (pH 3–10)
nonlinear IPG strips and in narrow pH gradients, pH 4.5–
5.5 and 4–5 (Amersham Biosciences). Strips were rehydrated
for 12 h at 30 V/cm in a buffer consisting of 7 M urea,
2 M thiourea, 2% CHAPS, 65 mM 1,4-DTT and 0.5% Phar-
malytes pH 3.5–9.5, 4.5–5.5 and 3.5–5 (according to IPG
strip pH range) (Amersham Biosciences) containing 90 mg
(50 mg for narrow pH ranges) of the protein sample. Strips
were focused at 207C, 49 000 V?h at a maximum of 8000 V
using the IPGphor system (Amersham Biosciences). For the
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second dimension, IPG strips were equilibrated for 20 min
in 6 M urea, 2% SDS, 20% glycerol, 375 mM Tris/HCl
(pH 8.8), reduced with 65 mM 1,4-DTT and alkylated with
135 mM iodoacetamide. The separation was performed in
12% T, 2.5% C constant concentration polyacrylamide slab
gels, run at 207C and 20 mA per gel and the fixed gels were
silver stained following the ammoniacal protocol [31]. For
semipreparative gels, the sample loading was increased to
400 mg/gel strip; other conditions were as above except that
the silver stain protocol was modified by omitting glutar-
aldehyde and formaldehyde from the sensitization and
impregnation solutions [32].
2.15 Data analysis
Triplicates of each sample were performed and scanned gels
were analysed with Image Master 2-D Platinum software
(Amersham Biosciences). Normalized spot volumes were
determined and expressed as mean 6 SD. Statistically sig-
nificant differences were computed by Student’s t-test,
ANOVA and Bonferroni, the significance level being set at
p ,0.05. Only proteins with spot volumes consistently dif-
ferent in all replicate gels were considered differentially
expressed [33].
2.16 HPLC-ESI-MS/MS
Excised gel spots were digested in situ with trypsin using an
Investigator ProGest (Genomic Solutions, Huntington, UK)
robotic digestion system [34, 35]. Lyophilized extracts were
redissolved in 0.1% formic acid prior to HPLC-MS/MS using
a Micromass Q-Tof Instrument interfaced to a CapLC chro-
matograph (Waters, Manchester, UK). Samples were injected
into a 300 mm615 mm Pepmap C18 column (LC Packings,
Amsterdam, NL), and eluted with an ACN/0.1% formic acid
gradient. The capillary voltage was set to 3500 V, and data-
dependent MS/MS acquisitions were performed on pre-
cursor ions with charge states of 2, 3 or 4 over a survey mass
range of 400–1300 Da. The collision gas was argon, and the
collision voltage was varied between 18 and 45 V depending
on precursor charge and mass. Proteins were identified by
correlation of uninterpreted tandem mass spectra to entries
in Swiss-Prot/TrEMBL, using ProteinLynx Global Server
(Versions 1.1, Micromass). The database was created by
merging the FASTA format files of Swiss-Prot, TrEMBL and
their associated splice variants. No taxonomic, mass or pI
constraints were applied. One missed cleavage per peptide
was allowed, and the fragment ion tolerance window was set
to 100 ppm. Carbamidomethylation of cysteine was
assumed, but no other modifications were considered. All
matching spectra were reviewed manually, and in cases were
the score reported by ProteinLynx Global Server was less
than 100, additional searches were performed against the
NCBI nr database using MASCOT, which utilizes a robust
probabilistic scoring algorithm [36]. Where identifications
were based on a single matching peptide, the sequences were
confirmed by manual sequencing using the MassLynx pro-
gram PepSeq. Measured parent and fragment masses were
typically within 0.03 Da of their calculated values.
3 Results
3.1 Patient characterization
We analysed biopsies of the distal portion of the left deltoid
muscle obtained from 11 FSHD patients (nine males and
two females) whose age ranged from 8 to 69 years. Their
clinical, genetic and histological features are reported in
Table 1.
The length of the diagnostic EcoRI fragment was dis-
tributed in the range of 10–27 kb. Although the patients with
shorter fragment or older age were most severely affected,
histological examination revealed minimal to mild myopathy
in all patients.
3.2 Expression profiling of single FSHD patients and
cluster analysis
The Human Muscle Array platform 2.0 ([37] and http://
muscle.cribi.unipd.it/microarrays/human.html) was used to
perform independent competitive hybridizations in which
RNAs purified from the 11 patients were compared with a pool
of ten different RNAs obtained from normal donors (mean age
35.9 6 13.5 years). Raw and normalized expression datasets
produced in this study are available at GEO database under the
series number GSE2820. To investigate the correlation between
transcriptome alterations and the number of KpnI repeats at
locus 4q35, the expression profiles of FSHD patients were clus-
tered using unsupervised hierarchical methods (Fig. 2 in this
article and Fig. A in Supplementary Information). Using Pear-
son correlation as distance measure, the three patients with age
at biopsy.50 (57.76 10 years) clustered together and younger
patients (mean age 30.7 6 8.5 years) clustered according to
EcoRI fragment length. Patientswith fragment length of 19 and
16 kbgroupedmore closely to the severely affectedpatientswith
10 kb fragment length (groups B and C, Fig. 2), while patients
with fragment longer than 20 kb and a milder phenotype con-
stituted a more distant cluster (group A, Fig. 2).
Probably, in older patients some features of normal aging
process and pathological degeneration are similar, compli-
cating identification of patterns of expression that are spe-
cific to FSHD. These patients were therefore excluded from
further analysis. The remaining eight patients were divided
into three groups on the basis of their EcoRI fragment size
(Fig. 2). Group A has fragments smaller than 21 kb (more
than 4 KpnI repeats left); group B ranges from 16 to 19 kb
(3–4 KpnI repeats) and group C has 10 kb fragments (a sin-
gle KpnI repeat). The complete list of differentially expressed
genes discriminating between group A patients and with age
at biopsy.50 years is reported in Table A in Supplementary
information.
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Figure 2. Hierarchical cluster analysis of the transcriptional expression profiles of 11 FSHD patients. Profiles were obtained using the Hu-
man Muscle Array 2.0 platform, which contains 4801 muscle cDNA probes and are expressed as FSHD deltoid/control. Pearson correlation
was used as a distance measure. Statistical support for the nodes of the dendrogram is also shown. We chose the bootstrapping genes
resampling procedure to build experimental dendrogram and 500 iterations. Patients are divided into four groups, according to their EcoRI
fragment length. Furthermore, patients with fragment longer than 20 kb and age at biopsy.50 years (mean 57.76 10) are separated from
younger (mean 25.76 5) patients with a comparable fragment size.
3.3 Proteome analysis
Proteomic analysis was performed on four groups of age-
matched male subjects, chosen among the 11 described
above: three FSHD with D4Z4 greater than 23 kb, three
FSHD with D4Z4 ranging from 16 to 21 kb and two FSHD
with 10 kb D4Z4 repeats (samples 2–4, 6–10 in Table 1).
Patients were compared to four normal donors (mean age
26.2 6 6.5 years) which were included in the pool of mRNA
controls. Triplicate samples were analysed by 2-DE using
pH 3–10 NL IPG strips. About 700 spots were detected and
their normalized spot volumes statistically evaluated. We
attempted to determine the common profile of proteins
associated with FSHD independently of fragment length.
Figure 3A shows two pH 3–10 NL 2-DE gels from healthy
and affected deltoid protein extracts. Spots significantly
altered in all FSHD samples compared to controls are indi-
cated and are listed in Table B in Supplementary informa-
tion. Figure 3B summarizes the up- and down-regulation of
proteins (indicated by their AC number) grouped in cate-
gories such as contractile and structural, oxidative metabo-
lism, anaerobic metabolism, degradation and oxidative
stress. Proteins associated with glycolysis and the tri-
carboxylic acid cycle are more abundant in patients, whereas
actin isoforms are down-regulated compared to controls.
Interestingly, a set of proteins involved in detoxification and
degradation processes (e.g. superoxide dismutase, peroxi-
redoxin 2 and a subunit of proteasome activator complex) are
down-regulated in patients. In contrast, elongation factor Tu,
involved in protein synthesis, is up-regulated. The differ-
ential expression of these proteins suggests a connection be-
tween free radicals homeostasis and muscle function. Some
of these differentially expressed proteins were also detected
by Laoudj-Chenivesse et al. [38] which is consistent with a
role for radical homeostasis in muscle function and FSHD
pathology. We also analysed the differentially expressed pro-
teins in relation to the three patient groups identified by
mRNA cluster analysis using ANOVA and the Bonferroni
test. Each class of patients is characterized by a specific set of
deregulated proteins. Functionally classified proteins which
discriminate between FSHD subgroups are listed in Table C
in Supplementary information. Some glycolytic enzymes are
preferentially up-regulated in group A suggesting a change
in muscle metabolism and consequently in fibre type com-
position [39]. Mitochondrial proteins are more significantly
altered in group B, while differential expression of molecules
with a role in developmental processes, signal transduction,
regulation of transcription, mRNA processing and stress
responses, is characteristic of group C.
A number of proteins involved in muscle differentiation
including COP9, HSP27, HSP70, a-crystallin, phosphogly-
cerate mutase and creatin kinase, are significantly changed
in all three classes of patients suggesting the involvement of
an upstream regulator. In order to correlate contractile pro-
tein composition to disease progression, the resolution of
contractile protein isoforms, including tropomyosins and
myosin light chains, was achieved using pH 4–5 and 4.5–5.5
narrow range IPG strips. Figures 4A and B show an expan-
sion of the pH 4.5–5.5 region of normal and affected sam-
ples; isoforms of myosin light chain and tropomyosin are
arrowed and differential expression data are summarized in
Table 3. Myosin alkali light chain slow isoform (MLC 1sb),
the regulatory light chain (MLC 2s) and its phosphorylatable
forms (MLC 2s1 and 2s2) [40] are more abundant in group C.
In contrast, the MLC 1f, 2f and 2f1 fast isoforms, are down-
regulated and the MLC 2f2 remains unchanged. Tropomyo-
sin isoforms reflect the MLC pattern, with down-regulation
of the fast isoform (a1) [41].
3.4 Transcriptional pattern
Similar data processing methodologies were applied to tran-
scriptomic data in order to discriminate genes associated
with disease condition from those which are altered as a
result of the physiological background.
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We identified about 50 transcripts which were up- or
down-regulated in all patients (see Table D in Supplementary
information) which we presume are linked to the disease
mechanism. About 20% correspond to genes with unknown
function. The known genes were assigned to functional
categories on the basis of literature and database annota-
tions. The largest category was involved in basal metabolism
(protein biosynthesis, degradation and oxidative phospho-
rylation). Others played a role in cell cycle control and devel-
opmental processes, including some transcription factors
specifically expressed in muscle (e.g. MEF2C), which may be
upstream regulators of gene cascades in muscle cells.
As a strategy for the identification of transcripts specifi-
cally associated with FSHD condition, we compared the
expression patterns of eight FSHD patients with the pub-
lished expression profiles of patients affected by other mus-
cular dystrophies, which were publicly available [21, 42]. To
this aim we analysed a dataset in which five LGMD (limb
girdle muscular dystrophy) 2B patients were analysed using
our Human Muscle Array 1.0 (http://muscle.cribi.unipd.it/)
[21] and a second dataset obtained from the analysis of six
DMD (Duchenne muscular dystrophy) patients using
another home-made muscle-specific platform [42]. The con-
cordant expression values from individual patients were
averaged and results are shown in Table 4. Among variably
expressed genes, only three (MYL3, CSRP3 and MEF2C)
show a correlated profile in all disorders, while most of them
are specifically altered in FSHD patients.
We then analysed differentially expressed transcripts in
the context of the three FSHD patients classes identified
above. Functionally categorized transcripts varying between
patient groups are reported in Table E and Fig. B of Supple-
mentary Information. In agreement with proteomic data,
glycolytic enzymes and cytoskeletal proteins are pre-
ferentially altered in group A, mitochondrial genes in
group B and molecules involved in development, signal
transduction, transcription regulation, mRNA processing
and stress responses, are more profoundly deregulated in
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Figure 3. (A) Representative 2-D gel images of healthy (control) and FSHD (fgmt = 10 kb) deltoid muscle. Proteins (90 mg) were separated on
18 cm 3–10 NL IPG strip followed by a second dimension in 24 cm626 cm 12% T polyacrylamide gel slab. All samples were run in triplicate.
Calibration of pI and Mr was performed with the calculated values of identified proteins using Image Master 2-D Platinum (Amersham
Biosciences) analysis software. Protein spots significantly altered are indicated together with the AC numbers (for p-values from Student’s
t-test see Table B in Supplementary information). (B) Graphical representation of differential protein expression between healthy (control)
and FSHD deltoid muscle. Histograms show four main functional categories significantly altered in these patients (for detailed results see
also Table B in Supplementary information). Spot volumes of the proteins (named by their Swiss-Prot accession number) are expressed in
terms of log2 (FSHD/Control).
group C. We also identified transcripts progressively up- or
down-regulated in the three classes of patients (Tables E and
F in Supplementary information), expression levels of these
transcripts contribute to disease severity and may illuminate
mechanisms of disease progression.
Transcripts with a decreasing profile include glycolytic
enzymes (e.g. GAPDH) which may be consistent with the
proposed coregulation of metabolic and contractile proteins
[43]. Many transcripts encoding structural proteins are
reduced, most of these are fast isoforms of sarcomeric pro-
teins. Most transcripts encoded by the mitochondrial ge-
nome (ATP6, cytochrome b, COX2 and NADH dehy-
drogenase subunit 1, 2, 4) are significantly up-regulated in
patients analysed in this study and COX3 shows a rising
expression profile, suggesting an increased oxidative metab-
olism (Tables D and E in Supplementary information).
3.5 MHC isoforms distribution
Proteomic and transcriptomic data imply a transition from a
fast to a slow muscle phenotype (Fig. 4). We paid particular
attention to the myosin heavy chain isoforms used to classify
human muscle fibres into type I or ‘slow oxidative red’
(MYH7 and MHC 1), type IIa or ‘fast oxidative red’ (MYH2
and MHC 2A) and IIx or ‘fast glycolytic white’ (MYH1 and
MHC 2X). Deltoideous muscle in healthy individuals typi-
cally comprises 50% slow and 50% fast fibres as assessed by
immunohistochemical or electrophoretic methods [39]. A
shift towards type I fibres has been reported in animal mod-
els and humans in response to stresses including endurance
training [44–47], pathological defects [48–52] and aging [53].
MHC isoforms were analysed by SDS electrophoresis
which provides a clear separation between fast (IIA and IIX)
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Table 3. Summary of differentially expressed proteins among FSHD groups obtained from narrow pH ranges gel
analysis
Spot
No.
Swissprot/
TrEMBL AC
Number
Protein Average ratios log2(FSHD/Control)
Group A Group B Group C
647 P06753 Tropomyosin alpha 3 slow 20.4 0.0 0.3
650 P09493 Tropomyosin alpha 1 fast 0.0 20.5 21.0
676 P08590 MLC 1sb (slow) 20.9 0.0 0.5
680 P05976 MLC 1f (fast) 20.5 20.9 21.1
692 P10916 MLC 2s (slow) 20.3 0.4 1.0
695 P10916 MLC 2s1 (slow) 20.2 20.9 0.4
693 P10916 MLC 2s2 (slow) 0.1 0.2 0.6
701 Q14843 MLC 2f (fast) 20.5 21.4 21.6
699 Q14843 MLC 2f1 (fast) 20.4 20.7 20.7
Figure 4. (A) Representative 2-D gel close-up images of muscle
protein extracts from healthy and diseased subjects in a 4.5–5.5
pH range showing MLC isoforms 1 (alkali) and 2 (phospho-
rilatable) characteristic of slow (s) and fast (f) fibres, respectively.
Muscle protein extract (50 mg) was cup-loaded on to an 18 cm gel
strip. Myosin light chain isoforms and their phosphorylation
degree are shown by arrow and the differential expression data
are summarized in Table 3. The phosphorylated isoforms were
confirmed by immunoblotting, utilizing antibodies against
phospho-serine sites of MLC fast and slows essential isoforms
(DaVinci Biochem), and by phosphoprotein staining using ProQ-
diamond, as described in [83]. (B) Representative 2-D gel close-
up images of muscle protein extracts from healthy and diseased
subjects in a 4–5 pH range showing Tropomyosin isoforms.
Muscle protein extract (50 mg) was cup-loaded on to an 18 cm gel
strip. Tropomyosin isoforms are shown by arrows and the differ-
ential expression data are summarized in Table 3.
and slow (I) myosin isoforms as shown in Fig. 5A [39]. Band
quantitation is performed as described in Section 2, signifi-
cant differences are indicated by asterisks (Fig. 5B). Pro-
gressive loss of MHC 2X from group A to group C with a
corresponding increase of MHC 1 (typical of slow fibres) is
Table 4. Expression values of a selected group of transcripts
commonly altered in FSHD muscles (this study) were
compared to values obtained in muscles affected by
Duchenne and Limb-Girdle 2B muscular dystrophies
(see text for details). Expression ratios from each sam-
ple belonging to the same disease were averaged and
the resulting value is shown in the table
Gene
name
Chr
pos
Averaged expression ratios
(disease vs control)
FSHMD1A DMD LGMD2B
ASB6 3 2.4 1.0 NA
COX2 MT 2.0 22.8 NA
IRAK1 X 1.9 1.0 NA
MB 22 1.8 1.0 1.0
EPHB4 7 1.7 1.0 NA
CTSB 8 1.6 1.0 NA
MRPS18 6 1.6 22.0 1.0
PPARA 22 1.6 NA 1.0
RNF26 11 1.5 1.0 NA
NEDD8 14 1.3 NA 1.0
ANK1 8 1.3 28.2 21.5
MYL2 12 1.3 NA 23.7
COX7C 5 21.3 NA 1.0
TAF7 5 21.4 1.0 NA
CCNI 4 21.4 NA 1.0
PKD1 1 21.5 1.0 NA
MYOD 11 22.1 1.0 NA
MYL3 3 1.5 4.7 1.9
CSRP3 11 1.1 3.9 1.0
MEF2C 5 21.2 22.0 NA
NA: not available.
observed. The expression profiles of MHC isoforms (Fig. 5B)
show progressive enrichment in MYH7 transcript in muscle
from FSHD patients. In group B a reduction of MYH1 fast
white transcript occurs, but levels of MYH2 fast red tran-
script are unchanged. Finally, in more severely affected
patients group (C), a significant decrease in both MYH2 and
MYH1 is observed.
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Table 5. Ratios values of the minimum set of transcripts discriminating with null error among the three classes of FSHD patients, identified
using supervised cluster analysis (PAM software, threshold = 2.0)
Human
muscle
array 2.0
archive ID
Gene name and biological process Chr
pos
Expression ratios (FSHD/control)
Group A Group B Group C
3–26 kb 4–23 Kb 6–21 Kb 7–19 Kb 8–16 Kb 9–10 Kb 10–10 Kb 11–10 Kb
Glycolysis
2-035G11 Enolase 3, (beta, muscle) (ENO3) 17 1.7 2.47 1.6 NA 1.14 NA 21.14 1.45
2-020G03 GAPDH 12 3.18 NA 2.43 21.05 1.1 21 1.08 1.01
2-001A03 GAPDH 12 1.31 1.38 1.29 1.07 21.1 21.03 1.1 21.07
2-018D10 Phosphoglycerate mutase 2 (muscle) 7 2.05 1.51 1.25 1.04 1.08 1 1.1 21.05
Oxidative phosphorylation
2-016E03 ATP synthase, H1 transporting, mitochondrial F0
complex, subunit b, isoform 1 (ATP5F1)
1 NA NA 1.02 1.61 1.69 1.02 1.04 1.07
2-027C03 ATP synthase, H1 transporting, mitochondrial F0
complex, subunit d (ATP5H)
12 NA NA 21.13 1.42 1.37 21.33 21.03 21.19
2-001G09 Cytochrome c oxidase subunit VIc 8 21.66 21.81 21.76 1.44 21 21.53 21.7 21.43
2-024G06 Cytochrome c oxidase subunit VIIa 19 1.19 1.39 21.01 21.11 21.22 21.24 21.09 21.22
2-021H06 Cytochrome c oxidase subunit VIIc 5 21.38 21.53 21.48 1.09 21.05 21.45 21.24 21.46
2-021H09 Cytochrome c oxidase subunit VIIc 5 21.61 21.51 21.66 1.04 1.18 21.41 21.25 21.29
2-002A02 NADH dehydrogenase (ubiquinone) 1 alpha
subcomplex, 4 (NDUFA4)
7 NA NA 21.24 1.51 1.3 NA 21.19 21.31
2-022G05 NADH dehydrogenase (ubiquinone) 1 beta
subcomplex, 9 (NDUFB9)
8 21.01 1.2 1.12 1.4 1.69 21.04 21.04 21.13
2-016D01 NADH dehydrogenase (ubiquinone) 1 alpha/beta
subcomplex, 1 (NDUFAB1)
16 21.11 21.43 21.48 1.01 1.04 21.11 21.14 21.03
2-015B08 NADH dehydrogenase (ubiquinone) flavoprotein 2
(NDUFV2)
18 NA 1.05 21.24 1.43 1.56 1.05 21.14 21.01
Protein biosynthesis
2-028E11 Ribosome-binding protein 1 (RRBP1) 20 1.14 1.15 1.12 1.52 1.56 1.83 1.28 1.51
2-018E08 Ribosomal protein L23a (RPL23A) 17 1.69 1.82 1.47 21.18 21.41 21.63 21.24 21.5
2-018F10 Mitochondrial ribosomal protein L33 2 NA 1.13 21.2 1.28 1.52 21.21 1.09 21.05
2-002H01 Ribosomal protein L13 (RPL13) 16 1.44 1.77 1.1 21.06 21.16 21.12 21.31 21.02
2-001C11 Ribosomal protein L21 (RPL21) 10 1.8 1.79 1.13 21.07 21.13 21.14 21.12 21.26
2-002F08 Ribosomal protein S19 (RPS19) 19 NA NA 1.39 21.24 21.2 1.03 21.27 1.26
2-018C10 Ribosomal protein S3A (RPS3A) 4 1.04 1.26 1.4 21.42 21.01 21.34 21.11 21.25
Proteolysis
2-012D09 Ubiquitin-conjugating enzyme E2G 1 17 NA NA 21.14 1.66 1.44 1.28 1.17 1.15
2-029A02 Cathepsin B (CTSB) 8 2.25 2.01 2.1 21.19 1.46 1.48 1.21 2.11
2-016G11 Neural precursor cell expressed, developmentally
down-regulated 8 (NEDD8)
14 NA NA 1.05 1.41 2.07 1.22 1.18 1.19
Transcripts codified by mitochondrial genome
2-041A01 12S Ribosomal RNA MT 21.03 21.18 21.96 1.46 21.04 1.07 21.61 1.68
2-041B06 NADH Dehydrogenase subunit 2 MT 1.16 1.66 1.54 NA 21.24 21.02 1.1 1.15
2-041A05 16 S Ribosomal RNA MT 1.47 21.09 21.4 1.51 1.32 21.49 23.05 21.2
2-041B12 Cytochrome oxidase subunit I (COX1) MT 1.21 2.09 1.09 2.46 1.51 21.19 21.23 21.21
2-035G10 Cytochrome oxidase subunit I (COX1) MT 21.06 1.41 1.19 2.79 1.79 21.31 21.29 1.01
Muscle contraction
2-013A06 PDZ and LIM domain 5 4 1.01 1.2 1.02 1.09 1.14 21.63 21.1 21.83
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Table 5. Continued
Human
muscle
array 2.0
archive ID
Gene name and biological process Chr
pos
Expression ratios (FSHD/control)
Group A Group B Group C
3–26 kb 4–23 Kb 6–21 Kb 7–19 Kb 8–16 Kb 9–10 Kb 10–10 Kb 11–10 Kb
2-022D04 Creatine kinase, muscle (CKM) 19 NA 3.02 2.44 21.09 21.16 1.12 1.04 1.11
2-020F04 Creatine kinase, muscle (CKM) 19 3.11 3.21 2.25 1.12 21.17 1.14 1.14 1.07
2-023H08 Creatine kinase, muscle (CKM) 19 2.99 2.98 1.8 1.05 21.26 1.06 1.24 1
2-001A02 Creatine kinase, muscle (CKM) 19 2.62 3.06 1.68 21.02 21.07 NA 1.28 21.06
2-023A02 Creatine kinase, muscle (CKM) 19 2.13 1.8 1.84 21.23 21.1 1.13 1.44 21.01
2-021E02 FATZ 1 (myozenin 1) 10 1.46 2.05 1.87 21.18 1.06 1.3 21 NA
2-021C11 Tropomyosin 2 (beta) 9 1.95 2.29 1.82 21.08 1.03 1.43 21.01 1.39
2-021C09 Muscle creatine kinase 19 2.48 2.46 1.35 21.09 21.05 1.05 1.22 1.07
2-021D12 Muscle creatine kinase 19 2.11 3.04 1.45 21.06 21.05 1.28 21 1
2-017B01 Solute carrier family 6 (neurotransmitter
transporter, creatine), member 8 (SLC6A8)
X 21 21.42 1.02 1.62 1.58 1.03 21.14 21.13
2-015D01 Titin (TTN) 2 1.27 NA 21.18 21.02 21.04 22.24 22.08 21.49
2-001A05 Titin-cap (telethonin) (TCAP) 17 1.88 2.28 1.84 21.13 21.33 NA 21.3 1.29
2-003E06 Tropomodulin 4 (muscle) (TMOD4) 1 2.23 1.75 1.97 21.04 21.03 21.25 1.03 21.08
2-001E09 Troponin C2, fast (TNNC2) 20 1.16 1.75 1.29 21.49 1.07 21.02 21.11 21.04
2-022H04 Troponin I, skeletal, fast (TNNI2) 11 NA 3.12 1.78 21.52 1.21 21.17 21.12 1.02
2-022B02 Troponin I, skeletal, fast (TNNI2) 11 1.95 2.7 1.64 NA 1.48 21.29 21.1 1.07
2-021B07 Troponin I, skeletal, slow (TNNI1) 1 NA 1.62 1.47 21.21 21.01 1.56 1.14 1.28
2-022B09 Troponin I, skeletal, slow (TNNI1) 1 1.8 1.39 1.39 21.22 21.01 1.44 21.14 1.27
2-021E03 Troponin T1, skeletal, slow (TNNT1) 19 2.35 3.35 1.88 21.45 1.16 1.14 1.16 1.31
2-024D08 vroponin T1, skeletal, slow (TNNT1) 19 2.51 3.55 2.3 1.05 1.15 1.13 1.09 1.32
2-007H03 Troponin T1, skeletal, slow (TNNT1) 19 2.99 2.45 1.45 1.09 1.09 21.01 1.09 1.12
2-014C03 Troponin T3, skeletal, fast (TNNT3) 11 1.37 1.4 1.45 21.42 21.01 21.05 1.1 1.03
Development
2-010H02 Tropomyosin 2 (beta) 9 2.19 1.75 1.54 21.09 1.29 NA 21.08 1.19
2-033C08 Plexin A2 (PLXNA2) 1 NA NA 21.07 2.07 1.58 21.03 1.53 1.14
2-018C06 Nebulin (NEB) 2 21.37 21.1 21.5 21.15 1.2 22.09 21.61 21.43
2-001G08 Myosin, light polypeptide 1, alkali; skeletal, fast
(MYL1)
2 22.03 21.02 1.04 21.02 2.11 NA 21.95 21.66
2-015F05 Neuroendocrine specific protein c
homolog; reticulon 4 (NOGO)
2 22.49 21.18 21.65 21.34 2.4 21.17 1.21 21.4
Cell cycle control
2-020D06 IGFBP7 4 NA 1.26 21.08 1.09 1.06 21.21 1.11 21.26
2-016G11 Neural precursor cell expressed, developmentally
down-regulated 8 (NEDD8)
14 NA NA 1.05 1.41 2.07 1.22 1.18 1.19
2-016F07 Protein phosphatase 2 (PPP2R3A) 3 NA 21.28 21.34 1.4 1.43 1.27 1.18 1.08
BL-003H11 Putative lymphocyte G0/G1 switch gene (G0S2) 1 2.64 2.29 1.28 21.57 1.1 21.18 21.38 21.62
Apoptosis
2-029A02 Cathepsin B (CTSB) 8 2.25 2.01 2.1 21.19 1.46 1.48 1.21 2.11
2-015F05 Neuroendocrine specific protein c homolog;
reticulon 4 (NOGO)
2 22.49 21.18 21.65 21.34 2.4 21.17 1.21 21.4
Regulation of transcription
2-004B03 H1 Histone family, member 2 (H1F2) 6 NA 21.33 21.25 1.61 1.36 1.15 1.15 1.02
2-024D01 Calreticulin (CALR) 19 NA NA 1.13 21.14 21.3 21.36 21.16 21.4
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Table 5. Continued
Human
muscle
array 2.0
archive ID
Gene name and biological process Chr
pos
Expression ratios (FSHD/control)
Group A Group B Group C
3–26 kb 4–23 Kb 6–21 Kb 7–19 Kb 8–16 Kb 9–10 Kb 10–10 Kb 11–10 Kb
2-030F04 Ankyrin repeat domain 1 10 21.02 1.49 1.17 2.05 1.65 1.06 21.23 1.03
2-030B09 DEK Oncogene (DNA binding) (DEK) 6 NA NA 1.03 NA 1.08 21.45 21.47 21.36
Signal transduction
2-030F04 Ankyrin repeat domain 1 10 21.02 1.49 1.17 2.05 1.65 1.06 21.23 1.03
2-030B09 DEK Oncogene (DNA binding) (DEK) 6 NA NA 1.03 NA 1.08 21.45 21.47 21.36
2-033C08 Plexin A2 (PLXNA2) 1 NA NA 21.07 2.07 1.58 21.03 1.53 1.14
2-016F07 Protein phosphatase 2 (formerly 2A), regulatory
subunit B (PR 72)
3 NA 21.28 21.34 1.4 1.43 1.27 1.18 1.08
2-029G10 RAB7, member RAS oncogene family (RAB7) 3 NA 1.08 1.22 21.06 21.28 21.6 21.3 21.38
BL-001A03 Ribosomal protein S27 (metallopanstimulin 1)
(RPS27)
1 1.22 1.52 21.08 21.14 21.7 22.1 21.35 21.51
BL-010D08 VAMP (vesicle-associated membrane
protein)-associated protein A, 33 kDa
9 NA 1.31 NA 21.45 21.36 NA 21.41 21.16
Calcium metabolism
2-024D01 Calreticulin (CALR) 19 NA NA 1.13 21.14 21.3 21.36 21.16 21.4
2-001G08 Myosin, light polypeptide 1, alkali; skeletal, fast
(MYL1)
2 22.03 21.02 1.04 21.02 2.11 NA 21.95 21.66
Immune response
2-030F04 Ankyrin repeat domain 1 10 21.02 1.49 1.17 2.05 1.65 1.06 21.23 1.03
2-029A02 Cathepsin B (CTSB) 8 2.25 2.01 2.1 21.19 1.46 1.48 1.21 2.11
Other
2-035F06 Heat shock protein, alpha-crystallin-related, B6
(HSPB6)
19 NA 21.12 21.41 NA 1.52 1.36 1.9 1.5
2-030D06 Acetyl-Coenzyme A transporter 3 NA 21.07 1.32 21.47 21.61 21.2 1.48 21.21
2-022G02 ARP1 Actin-related protein 1 homolog A,
centractin alpha (yeast) (ACTR1A)
10 NA 1.83 21.02 21.2 21.25 21.3 21.09 21.29
2-015E02 Adhesion regulating molecule 1 20 NA NA 1.05 1.39 1.25 21.03 21.01 1.04
2-022F06 FYVE and coiled-coil domain containing 1 (FYCO1) 3 21.56 21.24 21.07 21.04 1.3 1.41 1.4 1.45
2-023F12 ADP-Ribosylation-like factor 6 interacting protein 4 12 NA 9.07 2.98 NA 21.13 1.2 1.13 21.01
BL-002F03 Sorting nexin 17 (SNX17) 2 21.15 21.17 21.04 1.46 1.21 1.07 1.22 1.03
2-013E12 Serine (or cysteine) proteinase inhibitor, clade H
(heat shock protein 47), member 1 (SERPINH1)
11 1.61 1.67 1.46 21.15 21.01 1.16 21.11 1.06
2-005E03 PAI-1 mRNA-binding protein 1 NA NA 21.08 1.42 1.59 21.07 21.09 21.1
2-022C07 TNFAIP3 interacting protein 2 (TNIP2) 4 NA 1.7 1.29 21.04 21.12 21.09 1.35 1.01
2-014H04 RIO kinase 1 (yeast) (RIOK1) 6 NA 21 NA 1.6 1.53 1.65 1.06 1.48
BL-005E03 Cereblon (CRBN) 3 NA 21.32 21.17 2 1.28 21.07 21.09 1.02
Unknown
2-027D05 Chromosome 14 open reading frame 2 14 21.2 NA 21.35 1.47 1.21 21.14 21 21.1
2-015H06 Similar to RIKEN cDNA 1110030K22 11 2.13 1.97 1.87 21.09 1.15 1.2 1.01 1.06
2-033C05 KIAA0317 gene product 14 1.89 2.35 2.11 21.34 21.08 1.03 21.17 2.29
2-033F02 Hypothetical LOC339123 16 1.05 21.1 21.2 NA 1.27 1.54 1.47 1.93
2-031A04 Unknown sequence from clone RP11-391H12 13 1.12 NA 21.32 NA 2.5 1.58 1.25 1.57
2-008E10 Mid-1-related chloride channel 1 1 NA 1.03 NA 21.13 21.01 1.29 1.43 1.29
2-010D08 SIMILAR TO CG10671-like 14 NA NA 21.08 1.02 21.07 1.51 21.11 1.23
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Table 5. Continued
Human
muscle
array 2.0
archive ID
Gene name and biological process Chr
pos
Expression ratios (FSHD/control)
Group A Group B Group C
3–26 kb 4–23 Kb 6–21 Kb 7–19 Kb 8–16 Kb 9–10 Kb 10–10 Kb 11–10 Kb
2-029H10 Glioblastoma amplified sequence 7 21.6 21.48 21.47 21.06 1.23 21.41 21.58 21.5
2-032D02 Unknown sequence from clone CTD-3162L10 19 NA NA 1.42 21.58 21.3 NA NA 1.16
BL-005G03 DDHD domain containing 2 8 NA 21.18 21.11 1.38 1.33 1.14 1.21 1.14
2-020F06 Hypothetical protein MGC1203 1 2 1.76 1.31 1.85 1.5 NA 1.2 1.1
BL-003D02 Unknown sequence from clone HRPC837J1 17 21.35 21.25 21.38 1.03 1.16 NA 1.48 21.01
2-030H11 Unknown sequence from clone DKFZp313E0842 7 NA 1.04 21.08 1.82 1.28 1.13 1.07 21.01
2-015H03 Chromosome 3 open reading frame 10 3 NA 21.23 21.11 1.45 1.28 1.2 1.01 21.07
2-033B08 Unknown sequence from clone RP11-29M5 15 NA NA 1.15 21.66 21.72 21.4 21.65 21.09
2-027E08 Likely ortholog of mouse hypoxia induced gene 1 3 NA NA 21.12 1.29 1.1 21.23 21.43 21.12
BL-007F05 Unknown sequence from cosmid R26894 19 NA NA 1.52 21.4 21.38 21.52 21.02 21.16
2-028E04 RNA binding motif protein 22 (RBM22) 5 NA NA 21.13 1.13 1.19 21.12 21.14 21.16
2-037F04 Unknown sequence from clone RP5-856H6 6 NA 21.2 1.37 21.81 21.79 NA NA 21.17
BL-006E12 Unknown sequence from BAC RP11-383G6 3 NA NA 1.65 21.72 21.36 NA 21.33 21.19
2-006F04 Unknown sequence from BAC RP11-968A15 10 NA 21.21 1.1 21.76 21.45 NA 21.17 21.1
2-029E07 Unknown sequence from cDNA FLJ12005 fis 12 21.84 21.35 21.39 21.11 21.26 22.53 21.35 22.03
2-031G12 KIAA1036 protein 14 NA NA 21.04 1.99 1.53 1.05 1.09 21.04
2-030A11 Unknown sequence from BAC C-2555O16 14 NA 1 21.03 21.53 21.27 21.65 21.08 21.18
BL-003G12 Unknown sequence from clone RP11-258P13 11 NA 21.03 21.09 21.73 21.36 NA 21.36 21.22
2-032H02 Unknown sequence from BAC clone RP11-88L20 2 NA NA 1.04 1.97 1.78 1.03 1.18 1.15
2-033H08 Hypothetical protein DKFZp434L142 4 NA 21.03 21.01 21.5 21.44 21.3 21.62 21.26
BL-007D01 DNA Sequence from clone DAMA-213L4 on
chromosome 6
6 NA 1.01 NA 21.38 21.47 NA 1.04 21.16
2-037D03 Cirrhosis, autosomal recessive 1A (cirhin) (CIRH1A) 16 NA 1.18 1.15 21.56 21.49 NA NA 21
BL-001A11 Unknown sequence from clone b342k14 22 NA 21.2 1.05 21.82 21.48 21.31 1.15 21
Correlation between transcript and protein expression
levels of MHC are indicated in Fig. C in Supplementary
Information.
Determination of fibre type composition by immunohis-
tochemistry using muscle sections from the same patients
gave similar results (Table 2, Fig. 1), except for patient num-
ber 8, which reflects the normal variability among individ-
uals with a different genetic background.
3.6 MyoD target genes
Proteins of MyoD family and MADS domain proteins of
MEF2 family collaborate with other transcription factors to
establish myogenic cell lineages in the embryo, and are
essential for muscle-specific gene transcription [54–56].
MEF2C is induced late during myogenic differentiation and
has an important role in transducing calcium-regulated sig-
nals within skeletal muscle. As MEF2C, a known target of
MyoD transcription factor, is down-regulated in the micro-
array experiments, we hypothesized that this signalling cas-
cade is involved in FSHD pathology. MyoD expression levels
were investigated by quantitative RT-PCR and were reduced
in all three patient groups (see Table 7). Using the Genoma-
tix sequence analysis (MatInspector tool) we identified about
30 genes with putative-binding sites for MyoD or MEF2C in
their promoter region, which were altered in FSHD patients.
Some of these, according to literature, are known targets of
MyoD (such as MEF2C, TNNC2 and MYH1), while others
have not been identified before. Among these, HSP27 and
IkBa are involved in the canonical NF-kB activation pathway
[57–63]. Interestingly, each class of patients exhibited dereg-
ulation of a subset of MyoD target genes, not necessarily
altered in the other groups, suggesting different compensa-
tion mechanisms for the deficit of MyoD are operating. This
was also true for proteins known to be under MyoD control
including MHC 1 and 2X, HSP70, HSP27, phosphoglycerate
mutase and a-crystallin B.
Besides MEF2C, only titin, nebulin and MYH1 were
muscle-specific and down-regulated in all patients (Table H
in Supplementary information).
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C
Figure 5. (A) SDS-PAGE of mus-
cle protein extracts of molecular
weight markers, controls and
four FSHD groups, when 1 mg of
total extract was loaded. Elec-
trophoresis was carried out in a
discontinuous buffer system, in
a 6% T gel overnight at 207C and
100 V constant power. Proteins
were SYPRO Orange stained
and images were obtained by
Typhoon laser scanner. (B) Gra-
phical representation of MHC
fibre type composition (%) in
control and FSHD A, B, C,
groups. A group of patients with
age at biopsy .50 is also taken
into account. MHC isoforms
were analysed by SDS-PAGE
electrophoresis. Quantitation
was performed using Image
Quant (Molecular Dynamics)
software. Significant differences
compared to control are indi-
cated by asterisks. (C) Expres-
sion profiles of myosin heavy
chains typical of type I and II
fibres in deltoid muscle of indi-
viduals affected by FSHD. X-
axis: three classes of patients (A,
B and C); Y-axis: log2 expression
ratio (FSHD/control) of each
myosin transcript, averaged
among patients belonging to
the same class.
Table 6. Minimal promoter scanning of deregulated genes to search for common binding sites of V$MOKF transcription factor family.
Minimal promoter regions were analyzed using Genomatix Suite tool (Gene2Promoter) using default parameters as described in
Section 2
Gene
Name
mRNA
Accession
Number
Minimal
promoter
length
Consensus box sequence for
V$MOKF family
Strand
(1/2)
Consensus
box position
Gene expression ratios
(FSHD/control)
A B C
TNNI1 AK123965 2104,1501 ggctgtggctgggCCTTtgtg (1) 1350,1370 1.5 21.1 1.2
TNNI1 NM_003281 2101,1519 ttgcccctctgggCCTTcact (1) 1100,1120 1.5 21.1 1.2
SPAG7 NM_004890 2100,1518 cctccccgcggcgCCTTaaat (2) 1194,1214 1.5 1.1 1.2
SPAG7 NM_004890 2100,1518 tcctcacctcgggCCTTgcgc (2) 297,2117 1.5 1.1 1.2
PSMB5 NM_002797 2116,1839 tgctgcttcagcaCCTTgtta (2) 1402,1422 1.3 1.3 1.2
PSMB5 NM_002797 2116,1839 gacgttttcagtcACTTcctg (1) 1550,1570 1.3 1.3 1.2
MEF2C NM_002397 2190,1536 gacccacacagaaCCTTcaaa (2) 2121,2141 21.4 21.1 21.2
ZNF7 AK096025 2159,1501 cgccggaaacgggCCTTggcc (2) 210,1491 21.4 21.1 21.3
ZNF577 NM_032679 2107,1501 gggcaggcttgagCCTTtgag (1) 1183,1203 21.2 21.1 21.1
ZNF577 NM_032679 2107,1501 ccctcttttcgcgCCTTaaga (2) 1329,1349 21.2 21.1 21.1
TNNT3 NM_006757 2100,1515 tccatcagcgggaCCTTtcca (1) 199,1119 1.4 21.2 1.0
TNNC2 NM_003279 2103,1563 tgcccaatcagatCCTGgggt (2) 1465,1485 1.4 21.1 21.1
TNNC2 NM_003279 2103,1563 aggggactttgtgCCTTtact (1) 2142,2162 1.4 21.1 21.1
TNNT1 NM_003283 2100,1501 gcacacagtaggtCCTTggag (2) 1183,1203 2.5 1.0 1.2
LAMA4 AK027151 2101,1501 gtggtcatcagtcCCTTcata (2) 1141,1161 4.2 21.5 21.1
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Table 7. Expression ratios of selected transcription factors tested
by quantitative RT-PCR in affected deltoid muscle versus
control (p ,0.05)
Gene
name
Expression ratios (fshd/control)
Group A
Frgm. 21 kb
Group B
21 kb . Frgm
. 16 kb
Group C
Frgm = 10 kb
MYOD 22.0 21.8 22.5
MIDORI 21.4 21.6 21.8
MOK2 23.3 26.6 23.3
NFATC2 2 22.0 1.8
NFATC3 21.7 22.0 2
NFATC4 27.1 212.5 28.3
3.7 Identification of new gene cascades involved in
FSHD mechanism
We examined the promoter regions of transcriptional altered
genes in FSHD patients in order to identify other upstream
regulators of gene cascades that could be implicated in
FSHD.
Gene promoter analysis performed with Genomatix
sequence analysis tool (Gene2Promoter) identified a puta-
tive-binding site for MOK2 in several troponins and tran-
scription factors. MOK2 is highly expressed in skeletal mus-
cle and nervous system, and it is known to compete with
retinoblastoma protein (pRb) for the binding site on
lamin A/C [64]. In Table 6 are listed positions and sequences
of putative MOK2 consensus binding sites in the promoter
regions of genes that show an altered expression profile.
The promoter regions of titin and nebulin were searched
for common frames of transcription factors using Genoma-
tix software (GEMS Launcher package with the task ‘Defini-
tion of common frameworks’), enabling the identification of
a frame of ten putative transcription factor binding sites
which have been implicated in developmental/differentia-
tion processes and/or cell cycle control. One of these, the
transcription factor NFAT, is activated by calcineurin and it is
implicated both in fibre type transformation [65] and in
developmental processes [66]. Recent investigations [67] have
suggested that MEF2C acts in concert with NFAT to trans-
duce calcineurin signal to the slow fibre type-specific pro-
moters and that it is activated by calcineurin during skeletal
muscle differentiation [66]. Moreover, loss of specific NFAT
isoforms results in cardiovascular, skeletal muscle, cartilage,
neuronal or immune system defects [68–74].
Among the transcription factors identified by our study
as up-stream regulators of gene cascades, we chose as targets
for validation some muscle-specific factors with an estab-
lished role in developmental processes and/or skeletal mus-
cle fibre maturation. Quantitative RT-PCR tests performed
with pooled total RNA from the three FSHD patient groups
suggest that MOK2 and NFATs expression levels are altered
in FSHD muscle (Table 7).
4 Discussion
Our analysis has revealed significant differences in mRNA
and protein expression profiles in muscles of FSHD patients
compared to controls. Many differentially expressed genes
are unchanged in DMD or LGMD2B myopathies (see
Table 4), suggesting their specific association with the FSHD
condition. Nevertheless, a further validation in a larger group
of patients of each class as well as in a sample of more
severely affected muscles is necessary in order to verify their
specificity with higher significance.
We analysed the deltoideous muscle, which is the least
affected muscle and exhibited minimal to mild myopathic
features in all patients. Consequently, proteins and tran-
scripts changes are probably attributable to the primary
genetic lesion rather than secondary consequences of the
underlying pathology.
Hierarchical analysis of the expression profiles of eight
patients showing a different number of KpnI repeats at
4q35 locus clustered patients into three groups, according to
their D4Z4 arrangement (Fig. 2). Each group was char-
acterized by a specific collection of discriminating genes,
whose expression is increased or decreased according to
repeat number at D4Z4. As KpnI units number has been
shown to be a major factor in determining the clinical
severity of the disease [5], cluster analysis strongly suggests
that observed transcriptional alterations are relevant to
FSHD pathophysiology and could represent a molecular
link between primary genetic defect and phenotypic mani-
festation of the disease.
Integrating transcriptomic and proteomic analyses with
immunohistochemical data, bioinformatic investigation of
promoter regions and quantitative RT-PCR, enabled us to
identify a set of molecules probably involved in the onset
and progression of FSHD pathology. Our results suggest
that a crucial factor in disease progression could be a
defect in the MyoD-dependent gene network. This is con-
sistent with the observation that only rare regenerating
fibres can be detected in FSHD muscle. Our findings are
in agreement with a recent work by Winokur et al. [13]
which hypothesized that FSHD may arise from a particular
defect in the differentiation pathway of skeletal muscle
tissue. A significant number of differentially expressed
molecules seem to be target genes of MyoD (see Table H in
Supplementary information), as suggested by bioinfor-
matic analysis of their promoter regions. According to our
data, MyoD appears to be generally down-regulated in
FSHD muscles.
MEF2C, a calcium-regulated transcription factor which
functions synergistically with MyoD to activate transcription
and myogenesis, is underexpressed according to data
recently reported in a group of patients affected by FSHD
[13]. The MIDORI gene, a transcription factor which may
promote P19CL6 cells differentiation into cardiomyocytes
[75], is also down-regulated in FSHD. In addition, mRNAs
for the giant sarcomeric proteins titin and nebulin are all
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reduced, and mRNA for telethonin decreases according to
the number of KpnI repeat units at D4Z4 locus suggesting
an impairment in myofibrillogenesis.
Transcripts involved in muscle myogenesis were identi-
fied as differentially regulated supporting the hypothesis of
an impairment in cell differentiation and consequently in
myofibrillogenesis.
Proteomic analysis combined with transcript profiling
suggest a defect in cell differentiation. Cell cycle regulators,
such as NEDD8 gene product, a small protein with sequence
similarity to ubiquitin that plays a central role in differentia-
tion via degradation of cell cycle regulators such as p21 and
cyclin D [76], and Hsp70, an Hsc70 homologue involved in
cyclin maturation [77], are down-regulated. NEDD8 acts as
an activation signal for the Cul-family of proteins, resulting
in cell cycle arrest, while the increment of COP9 signalo-
some could counteract the NEDD8 activity by cleaving
NEDD8 from the CUL1 subunit of SCF ubiquitin ligases
which are essential factors for the processing of NF-kB pre-
cursor p105 [57]. NF-kB functions as a negative regulator of
myogenesis by inhibiting MyoD [78] and has been implicated
in muscle wasting subsequent to disease [79]. In the classic
activation pathway, NF-kB is sequestered into the cytoplasm
via its association with IkBa. After cytokine stimulation
(TNFa or IL1), the IkBa is ubiquitinated and degraded by the
26S proteasome complex releasing NF-kB which is rapidly
translocated into the nucleus, where it activates the tran-
scription of specific genes [63]. Recently, it has been shown
that HSP27 enhances degradation of phosphorylated IkBa
through the ubiquitin–proteasome pathway [59]. Our data
show that IkBa gene expression decreases according to the
number of KpnI repeat units at D4Z4 locus and that HSP27
protein is up-regulated in all FSHD patients. Additionally,
IRAK1 and RhoC, which are known NF-kB activators, are
also up-regulated. These observations could suggest that NF-
kB activity is increased, and may induce further loss of MyoD
mRNA in FSHD muscle, which in turn interferes with ske-
letal muscle differentiation [79].
Transcriptional, proteomic and histochemical analyses
all support the presence of an increased number of type I
fibres in severely affected FSHD muscle. Current under-
standing of molecular regulation of skeletal muscle fibre
type suggests that each fibre type may be controlled by
multiple signalling pathways and transcription factors reg-
ulating a specific functional gene grouping. Several lines of
evidence implicate the calcineurin-NFAT pathway in fibre
type transformation [80, 81]. While direct evidence about
involvement of calcineurin signalling in FSHD is still lack-
ing, our data show altered regulation of several known
downstream effectors of calcineurin, for example MEF2C,
NF-kB, NF-ATc2-c4. Lin et al. [82] indicated the peroxisome
proliferator-activated receptor gamma coactivator 1a (PGC-
1a), a regulator of mitochondrial biogenesis in vivo, as the
principal physiologic regulator for type I fibre specification
in mice. Considering the significant up-regulation of several
mitochondrial genes in our patients, it would be interesting
to determine PGC-1a expression level in FSHD condition to
assess if this factor could be responsible for the observed
fibre switch.
The changed proportion of slow fibres in FSHD muscle
may be either the result of a decreased muscular activity in
the most affected patients or a physiological adaptation to the
pathological condition. The increased number of slow fibres
could be the consequence of a failure of proper regeneration
of the adult muscle. According to this hypothesis, if the pri-
mary lesion is a deficit in one or more factors triggering
embryonic myogenesis, then the defect emerges also during
the regeneration of satellite cells in the adult tissue. We hy-
pothesize that FSHD muscle does not synthesize fast fibres
properly because of the primary defect, so muscle cells
damaged by mechanical stress are not replaced sufficiently
by newly differentiated myotubes, leading to progressive
muscular weakness. A further hypothesis for the imbalance
between fast and slow-type fibres in the analysed dystrophic
muscles could be that fast FSHD fibres are more susceptible
to early apoptotic death signalling, and consequently the
proportion of slow fibres increases in differentiated affected
muscle. This phenomenon has been established, for exam-
ple in muscles that undergo atrophy following aging and
sarcopenia [83]. However, our data have been produced from
adult FSHD muscle and show neither the presence of apop-
totic fibres by histopathological analysis nor a deregulation of
transcripts or proteins with key roles in the apoptotic path-
ways by transcriptome/proteome analysis. Probably, to
explore the hypothesis of a specific loss of fast fibres by
apoptosis, it will be more convenient to analyse possible
impairments of FSHD muscle cell differentiation in vitro,
using a human primary culture model.
Comparative differential proteomic studies on human
aged muscles indicate that MLC phosphorylated isoforms
are unchanged in FSHD patients compared to aged subjects
despite the similar distribution of MHC [84]. In addition,
most proteins involved in oxidative stress responses are
decreased according to the KpnI repeats number, which
reflects a progressive inability of antioxidant defences to
maintain cellular homeostasis. Oxidative damage to DNA,
proteins and lipids in mitochondria is associated to degen-
erative conditions [85, 86] and aging [87]. Moreover, the
reactive oxygen species (ROS) activate NF-kB, which may
trigger muscle atrophy as well as inflammatory responses.
Alternatively (or concomitantly), ROS may damage the
mitochondrial membrane, altering the flux of calcium ions
inside the cell promoting protein degradation [88] and apop-
tosis [89]. The alteration of expression of the Ca21-dependent
transcription factors NFATs and MEF2C and signalling
molecules such as calmodulin and troponin C, probably
amplifies the degenerative process via a positive feedback
mechanism.
Several transcripts of genes encoding contractile proteins
decreased according to KpnI repeats number at D4Z4 locus.
Cathepsin B and other transcripts with protein degradation
associated roles were increased in parallel with disease
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severity. In atrophic muscle, up-regulation of genes involved
in proteolysis contributes to decreased protein content in
muscle fibre which may be a key factor in the down-regula-
tion of contractile proteins observed at proteome level.
Our data do not provide any evidence of altered expres-
sion of the 4q35 genes ANT1, FACL2, ALP or ARGBP2 con-
sistent with previous studies [8–10, 13]. However, we
observed significant changes in the expression level of some
genes mapping into the more centromeric region of the long
arm of chromosome 4, unfortunately not supported by sta-
tistical analysis. A tempting hypothesis recently proposed by
Masny et al. [14] states that FSHD may arise from improper
interactions of 4qter with transcription factors or chromatin
modifiers at the nuclear envelope. Many transcription factors
depend on nuclear lamins interactions for their activation.
Among these, MOK2 competes with pRb for the same bind-
ing site to lamin A/C [64] and our data show it is under-
expressed in FSHD.
In conclusion, our study combining proteomic, tran-
scriptional and bioinformatic analyses, supports the role of
KpnI repeats number on global expression pattern of FSHD
patients and suggests the alteration in gene expression and
protein synthesis is not secondary to pathological processes
but can be attributed to the contraction at 4q35.
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